HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53
Cancer Cell International,
Abstract Background Pancreatic ductal adenocarcinoma (PDAC), as a highly lethal malignancy with high mortality, lacks of…